AIDSinfo Releases Fact Sheet on Symtuza, a New Combination Drug to Treat Certain Adults with HIV
August 27, 2018
On July 17, 2018, the Food and Drug Administration (FDA) approved Symtuza, a new combination antiretroviral drug to treat HIV infection in adults:
- who have never taken HIV medicines before, or
- who have a viral load less than 50 copies per mL, have been on a stable treatment regimen for at least 6 months, and have no known substitutions associated with resistance to darunavir or tenofovir.
The 4-drug (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) fixed-dose combination tablet is a complete regimen for the treatment of HIV infection and should not be used with other HIV medicines.
For more information on Symtuza, please see the AIDSinfo Symtuza fact sheet [en español].
Do you want to learn more about HIV medicines? Check out the AIDSinfo FDA-Approved HIV Medicines fact sheet.